Exposure to Infliximab During Pregnancy: Post-Marketing Experience

ConclusionsThe observed prevalence of adverse pregnancy and infant outcomes including congenital anomalies following exposure to IFX did not exceed estimates reported for the general population and no unexpected patterns were observed.

Source: Drug Safety - October 31, 2019 Category: Drugs & Pharmacology Source Type: research